Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Victoria Sales/Ceclor imports

Executive Summary

The New York-based firm was the U.S. importer of a shipment of the Lilly antibiotic whose handling by a series of Hong Kong and Singapore trading companies was described in testimony at an April 16 hearing of Chairman Dingell's House Energy & Commerce/Oversight & Investigations subcmte. The shipment was not counterfeit Ceclor, as incorrectly reported in a previous story on the hearing ("The Pink Sheet" April 21, p. 12). Subcmte. staffer Stephen Sims explained the findings of a staff delegation's trip to several Pacific Rim countries. He said in testimony that in Singapore the congressional group "was primarily interested in the shipment of an Eli Lilly antibiotic product, Ceclor, to the United States in the summer and fall of 1985." Sims said in his testimony: "According to the chief pharmacist of Oscar [a Singapore trading company], the company bought Ceclor from the J.L. Morrison Co. in Malaysia, an authorized Lilly distributor. Oscar's purchase was in response to an order form Galaxy International, a Hong Kong trading company. Oscar said that, because sales were low in Malaysia, Morrison was eager to make the sale, even though the volume ordered was obviously too large for Oscar's normal requirements. The Ceclor was delivered personally to Oscar by Morrison's sales manager, who flew with the goods to Singapore. As instructed by Galaxy, Oscar shipped the goods to Victoria Sales in New York".

You may also be interested in...

Pfizer Upjohn’s Ray On Changing The Grave Trajectory Of NCDs

Pfizer Upjohn’s Global President of R&D and Medical, Amrit Ray, talks in a wide-ranging interview about the need for tailored interventions to address the growing burden of non-communicable diseases and efforts around harnessing real world data. He also underscores the importance of investing in primary care and a primary health workforce against the backdrop of outbreaks such as coronavirus.

QUOTED. 24 February 2020. Daniel Taddeo.

Political tensions between Switzerland and the EU have led to concerns about the future status of the only Swiss medtech notified body, SQS. Here’s what SQS board member Daniel Taddeo said about the situation.

Herbalife 'Just Getting Started' On Growth Following Flat 2019 At $4.9bn Net Sales

"We're a growth company, well-positioned in a global trend of nutrition that the world hasn't seen before," says co-president John Agwunobi. But the direct seller's record volume increase in 2019 didn’t translate to revenue growth as China, Mexico and Central and South America pulled down results.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts